Aurintricarboxylic acid is a canonical disruptor of the TAZ-TEAD transcriptional complex

被引:5
|
作者
Che, Kepeng [1 ]
Pobbati, Ajaybabu, V [1 ]
Seavey, Caleb N. [1 ,2 ]
Fedorov, Yuriy [3 ]
Komar, Anton A. [4 ,5 ]
Burtscher, Ashley [1 ]
Ma, Shuang [1 ]
Rubin, Brian P. [1 ,6 ]
机构
[1] Cleveland Clin, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44106 USA
[2] Cleveland Clin, Digest Dis & Surg Inst, Dept Gen Surg, Cleveland, OH 44106 USA
[3] Case Western Reserve Univ, Sch Med, Small Mol Drug Dev Core, Cleveland, OH USA
[4] Cleveland State Univ, Ctr Gene Regulat Hlth & Dis, Dept Biol Geol & Environm Sci, Cleveland, OH 44115 USA
[5] Cleveland Clin, Lerner Res Inst, Genom Med Inst, Cleveland, OH 44106 USA
[6] Cleveland Clin, Robert J Tomsich Pathol & Lab Med Inst, Cleveland, OH 44106 USA
来源
PLOS ONE | 2022年 / 17卷 / 04期
关键词
HIPPO PATHWAY; YAP; YAP/TAZ; COACTIVATORS; PEPTIDES; FUSION;
D O I
10.1371/journal.pone.0266143
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Disrupting the formation of the oncogenic YAP/TAZ-TEAD transcriptional complex holds substantial therapeutic potential. However, the three protein interaction interfaces of this complex cannot be easily disrupted using small molecules. Here, we report that the pharmacologically active small molecule aurintricarboxylic acid (ATA) acts as a disruptor of the TAZ-TEAD complex. ATA was identified in a high-throughput screen using a TAZ-TEAD AlphaLISA assay that was tailored to identify disruptors of this transcriptional complex. We further used fluorescence polarization assays both to confirm disruption of the TAZ-TEAD complex and to demonstrate that ATA binds to interface 3. We have previously shown that cell-based models that express the oncogenic TAZ-CAMTA1 (TC) fusion protein display enhanced TEAD transcriptional activity because TC functions as an activated form of TAZ. Utilizing cell-based studies and our TC model system, we performed TC/TEAD reporter, RNA-Seq, and qPCR assays and found that ATA inhibits TC/TEAD transcriptional activity. Further, disruption of TC/TEAD and TAZ/TEAD interaction by ATA abrogated anchorage-independent growth, the phenotype most closely linked to dysregulated TAZ/TEAD activity. Therefore, this study demonstrates that ATA is a novel small molecule that has the ability to disrupt the undruggable TAZ-TEAD interface.
引用
收藏
页数:16
相关论文
共 50 条
  • [31] Direct YAP/TAZ-TEAD inhibitor paves the way toward realizing cancer mechanomedicine
    Papavassiliou, Kostas A.
    Gargalionis, Antonios N.
    Papavassiliou, Athanasios G.
    PHARMACOLOGICAL RESEARCH, 2024, 206
  • [32] YAP1/TAZ-TEAD transcriptional networks maintain skin homeostasis by regulating cell proliferation and limiting KLF4 activity
    Yuan, Yao
    Park, Jeannie
    Feng, Amber
    Awasthi, Parirokh
    Wang, Zhiyong
    Chen, Qianming
    Iglesias-Bartolome, Ramiro
    NATURE COMMUNICATIONS, 2020, 11 (01)
  • [33] Targeting YAP/TAZ-TEAD signaling as a therapeutic approach in head and neck squamous cell carcinoma
    Sato, Kuniaki
    Faraji, Farhoud
    Cervantes-Villagrana, Rodolfo Daniel
    Wu, Xingyu
    Koshizuka, Keiichi
    Ishikawa, Tomohiko
    Iglesias-Bartolome, Ramiro
    Chen, Lei
    de Marval, Paula L. Miliani
    Gwaltney, Stephen L.
    Adler, Benjamin
    Gutkind, J. Silvio
    CANCER LETTERS, 2025, 612
  • [34] Targeting TAZ-TEAD in minimal residual disease enhances the duration of targeted therapy in melanoma models
    Ott, Connor A.
    Purwin, Timothy
    Tiago, Manoela
    Lou, Kristine
    Chen, Pan-Yu
    Chowdhury, Somaneth
    Mersky, Glenn
    Hacohen, Nir
    Lamar, John
    Capparelli, Claudia
    Bollag, Gideon
    Aplin, Andrew
    CANCER RESEARCH, 2024, 84 (06)
  • [35] YAP1/TAZ-TEAD transcriptional networks maintain skin homeostasis by regulating cell proliferation and limiting KLF4 activity
    Yao Yuan
    Jeannie Park
    Amber Feng
    Parirokh Awasthi
    Zhiyong Wang
    Qianming Chen
    Ramiro Iglesias-Bartolome
    Nature Communications, 11
  • [36] Antitumor activity of novel and potent YAP/TAZ-TEAD inhibitorstargeting the Hippo pathway in solid tumors
    Kim, Jisook
    Jung, Seung Hyun
    Han, Seon Yeong
    Yoon, Jihee
    Kim, Minjeong
    Byun, Jooyun
    Moon, Heesun
    Lee, Eunyoung
    Kim, Yu-Yon
    Park, Hyunjin
    Jeon, Ye
    Ahn, Young Gil
    Kim, Young Hoon
    Suh, Kwee Hyun
    CANCER RESEARCH, 2023, 83 (07)
  • [37] The Hippo Pathway Effectors YAP/TAZ-TEAD Oncoproteins as Emerging Therapeutic Targets in the Tumor Microenvironment
    Mokhtari, Reza Bayat
    Ashayeri, Neda
    Baghaie, Leili
    Sambi, Manpreet
    Satari, Kosar
    Baluch, Narges
    Bosykh, Dmitriy A. A.
    Szewczuk, Myron R. R.
    Chakraborty, Sayan
    CANCERS, 2023, 15 (13)
  • [38] Identification of Celastrol as a Novel YAP-TEAD Inhibitor for Cancer Therapy by High Throughput Screening with Ultrasensitive YAP/TAZ-TEAD Biosensors
    Nouri, Kazem
    Azad, Taha
    Ling, Min
    van Rensburg, Helena J. Janse
    Pipchuk, Alexander
    Shen, He
    Hao, Yawei
    Zhang, Jianmin
    Yang, Xiaolong
    CANCERS, 2019, 11 (10)
  • [39] INHIBITION OF YAP/TAZ-TEAD DEPENDENT TRANSCRIPTION UNDERLIES THE ANTI-MITOGENIC EFFECTS OF CAMP IN VSMC
    Kimura, T. E.
    Duggirala, A.
    Newby, G. N.
    Newby, A. C.
    Bond, M.
    ATHEROSCLEROSIS, 2016, 244 : E7 - E8
  • [40] Yap/Taz-TEAD activity links mechanical cues to progenitor cell behavior during zebrafish hindbrain segmentation
    Voltes, Adria
    Hevia, Covadonga F.
    Engel-Pizcueta, Carolyn
    Dingare, Chaitanya
    Calzolari, Simone
    Terriente, Javier
    Norden, Caren
    Lecaudey, Virginie
    Pujades, Cristina
    DEVELOPMENT, 2019, 146 (14):